Gernot Zissel

List of Publications by Year
in descending order

97 papers	5,830 citations	70961 41 h-index	76769 74 g-index
102 all docs	102 docs citations	102 times ranked	6989 citing authors

#	Article	IF	Citations
1	A Vicious Circle of Alveolar Macrophages and Fibroblasts Perpetuates Pulmonary Fibrosis via CCL18. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 781-792.	2.5	403
2	Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. European Respiratory Journal, 2007, 29, 976-985.	3.1	315
3	Serum CC-Chemokine Ligand 18 Concentration Predicts Outcome in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 717-723.	2.5	290
4	Alternatively activated alveolar macrophages in pulmonary fibrosisâ€”mediator production and intracellular signal transduction. Clinical Immunology, 2010, 137, 89-101.	1.4	268
5	Sarcoidosis: TNF- Î± Release from Alveolar Macrophages and Serum Level of sIL-2R Are Prognostic Markers. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1586-1592.	2.5	228
6	CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis. Arthritis and Rheumatism, 2007, 56, 1685-1693.	6.7	202
7	The Serotoninergic Receptors of Human Dendritic Cells: Identification and Coupling to Cytokine Release. Journal of Immunology, 2004, 172, 6011-6019.	0.4	190
8	Extracellular Adenosine Triphosphate and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 928-934.	2.5	174
9	Pulmonary TH2 response in Pseudomonas aeruginosaâ€“infected patients with cystic fibrosis. Journal of Allergy and Clinical Immunology, 2006, 117, 204-211.	1.5	172
10	Macrophage Activation in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. PLoS ONE, 2015, 10, e0116775.	1.1	170
11	Inhaled Vasoactive Intestinal Peptide Exerts Immunoregulatory Effects in Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 540-548.	2.5	146
12	Phenotyping Sarcoidosis from a Pulmonary Perspective. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 330-336.	2.5	137
13	P2X₇ Receptor Signaling in the Pathogenesis of Smoke-Induced Lung Inflammation and Emphysema. American Journal of Respiratory Cell and Molecular Biology, 2011, 44, 423-429.	1.4	130
14	Serum Level of Interleukin 8 Is Elevated in Idiopathic Pulmonary Fibrosis and Indicates Disease Activity. American Journal of Respiratory and Critical Care Medicine, 1998, 157, 762-768.	2.5	120
15	Purinergic Receptor Inhibition Prevents the Development of Smoke-Induced Lung Injury and Emphysema. Journal of Immunology, 2010, 185, 688-697.	0.4	119
16	Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients. European Respiratory Journal, 2006, 27, 1190-1195.	3.1	116
17	Lung Collagens Perpetuate Pulmonary Fibrosis via CD204 and M2 Macrophage Activation. PLoS ONE, 2013, 8, e81382.	1.1	102
18	Alveolar macrophages are the main source for tumour necrosis factorâ€Î± in patients with sarcoidosis. European Respiratory Journal, 2003, 21, 421-428.	3.1	97

#	Article	IF	Citations
19	The P2Y14 Receptor of Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2005, 33, 601-609.	1.4	90
20	Sarcoidosis-Immunopathogenetic Concepts. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 003-014.	0.8	86
21	Purinergic Receptor Type 6 Contributes to Airway Inflammation and Remodeling in Experimental Allergic Airway Inflammation. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 215-223.	2.5	85
22	Anti-inflammatory cytokine release by alveolar macrophages in pulmonary sarcoidosis.. American Journal of Respiratory and Critical Care Medicine, 1996, 154, 713-719.	2.5	83
23	Chemokines Indicate Allergic Bronchopulmonary Aspergillosis in Patients with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1370-1376.	2.5	83
24	Immunologic Response of Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 390-403.	0.8	82
25	Genetics of Sarcoidosis. Clinics in Chest Medicine, 2008, 29, 391-414.	0.8	80
26	Pulmonary chemokines and their receptors differentiate children with asthma and chronic cough. Journal of Allergy and Clinical Immunology, 2005, 115, 728-736.	1.5	70
27	Genotype-corrected reference values for serum angiotensin-converting enzyme. European Respiratory Journal, 2006, 28, 1085-1091.	3.1	66
28	Serotoninergic Receptors on Human Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2007, 36, 85-93.	1.4	65
29	Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2002, 19, 185-90.	0.2	64
30	Essential Role of Osteopontin in Smoking-Related Interstitial Lung Diseases. American Journal of Pathology, 2009, 174, 1683-1691.	1.9	59
31	Prostaglandin E2reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3. FEBS Letters, 2002, 518, 154-158.	1.3	58
32	Activation of Human Alveolar Macrophages via P2 Receptors: Coupling to Intracellular Ca2+ Increases and Cytokine Secretion. Journal of Immunology, 2008, 181, 2181-2188.	0.4	57
33	POLYMORPHISMS AT POSITION â[^]'308 IN THE PROMOTER REGION OF THE TNF-Î± AND IN THE FIRST INTRON OF THE TNF-Î² GENES AND SPONTANEOUS AND LIPOPOLYSACCHARIDE-INDUCED TNF-Î± RELEASE IN SARCOIDOSIS. Cytokine, 1999, 11, 882-887.	1.4	55
34	IL-10â€"producing monocytes differentiate to alternatively activated macrophages and areÂincreased in atopic patients. Journal of Allergy and Clinical Immunology, 2007, 119, 464-471.	1.5	55
35	Human alveolar epithelial cells type II are capable of TGFÎ²-dependent epithelial-mesenchymal-transition and collagen-synthesis. Respiratory Research, 2018, 19, 138.	1.4	52
36	A Novel Sarcoidosis Risk Locus for Europeans on Chromosome 11q13.1. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 877-885.	2.5	51

#	Article	IF	Citations
37	<i>Atopobium</i> and <i>Fusobacterium</i> as novel candidates for sarcoidosis-associated microbiota. European Respiratory Journal, 2017, 50, 1600746.	3.1	46
38	CC-Chemokine Ligand 18 Induces Epithelial to Mesenchymal Transition in Lung Cancer A549 Cells and Elevates the Invasive Potential. PLoS ONE, 2013, 8, e53068.	1.1	45
39	A role for MCP-1/CCR2 in interstitial lung disease in children. Respiratory Research, 2005, 6, 93.	1.4	44
40	Pathogenesis of sarcoidosis. Presse Medicale, 2012, 41, e275-e287.	0.8	44
41	CCR2 and CXCR3 agonistic chemokines are differently expressed and regulated in human alveolar epithelial cells type II. Respiratory Research, 2005, 6, 75.	1.4	43
42	Interleukin-13 acts as an apoptotic effector on lung epithelial cells and induces pro-fibrotic gene expression in lung fibroblasts. Clinical and Experimental Allergy, 2008, 38, 619-628.	1.4	43
43	Genome-wide association analysis reveals 12q13.3â€“q14.1 as new risk locus for sarcoidosis. European Respiratory Journal, 2013, 41, 888-900.	3.1	43
44	Kinetics of Torque Teno Virus-DNA Plasma Load Predict Rejection in Lung Transplant Recipients. Transplantation, 2019, 103, 815-822.	0.5	40
45	Cellular Players in the Immunopathogenesis of Sarcoidosis. Clinics in Chest Medicine, 2015, 36, 549-560.	0.8	39
46	Human alveolar epithelial cells induce nitric oxide synthaseâ€2 expression in alveolar macrophages. European Respiratory Journal, 2002, 19, 672-683.	3.1	38
47	Altered purinergic signaling in the tumor associated immunologic microenvironment in metastasized non-small-cell lung cancer. Lung Cancer, 2015, 90, 516-521.	0.9	35
48	Systemic Immune Cell Activation in a Subgroup of Patients with Idiopathic Pulmonary Fibrosis. Respiration, 2003, 70, 262-269.	1.2	34
49	Analysis of the Kveim-Siltzbach Test Reagent for Bacterial DNA. American Journal of Respiratory and Critical Care Medicine, 1999, 159, 1981-1984.	2.5	33
50	Tumor-Cell Co-Culture Induced Alternative Activation of Macrophages Is Modulated by Interferons<i>In Vitro</i>. Journal of Interferon and Cytokine Research, 2012, 32, 169-177.	0.5	30
51	Functional Toll-Like Receptor 9 Expression and CXCR3 Ligand Release in Pulmonary Sarcoidosis. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 749-757.	1.4	29
52	Serum Level of CC-Chemokine Ligand 18 Is Increased in Patients with Non-Small-Cell Lung Cancer and Correlates with Survival Time in Adenocarcinomas. PLoS ONE, 2012, 7, e41746.	1.1	29
53	Uridine supplementation exerts anti-inflammatory and anti-fibrotic effects in an animal model of pulmonary fibrosis. Respiratory Research, 2015, 16, 105.	1.4	28
54	The purinergic receptor subtype P2Y2 mediates chemotaxis of neutrophils and fibroblasts in fibrotic lung disease. Oncotarget, 2017, 8, 35962-35972.	0.8	28

#	Article	IF	Citations
55	P2Y6 Receptor Activation Promotes Inflammation and Tissue Remodeling in Pulmonary Fibrosis. Frontiers in Immunology, 2017, 8, 1028.	2.2	27
56	Cellular Activation in the Immune Response of Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2014, 35, 307-315.	0.8	25
57	Sarcoidosis: historical perspective and immunopathogenesis (part I). Respiratory Medicine, 1998, 92, 126-139.	1.3	24
58	HOPE-Fixation Enables Improved PCR-Based Detection and Differentiation of Mycobacterium tuberculosis Complex in Paraffin-Embedded Tissues. Pathology Research and Practice, 2003, 199, 619-623.	1.0	23
59	TCR V Î² Families in T Cell Clones from Sarcoid Lung Parenchyma, BAL, and Blood. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1593-1600.	2.5	22
60	Anti-<I>Borrelia burgdorferi</I> immunoglobulin seroprevalence in pulmonary sarcoidosis: a negative report. European Respiratory Journal, 1997, 10, 1356-1358.	3.1	22
61	Shed soluble ICAM-1 molecules in bronchoalveolar lavage cell supernatants and serum of patients with pulmonary sarcoidosis. Lung, 1997, 175, 105-116.	1.4	20
62	Functional characterization of histamine receptor subtypes in a human bronchial epithelial cell line. International Journal of Molecular Medicine, 2006, 18, 925-31.	1.8	20
63	Interleukin-18 expression by alveolar epithelial cells type II in tuberculosis and sarcoidosis. FEMS Immunology and Medical Microbiology, 2006, 46, 30-38.	2.7	19
64	Association Study for 26 Candidate Loci in Idiopathic Pulmonary Fibrosis Patients from Four European Populations. Frontiers in Immunology, 2016, 7, 274.	2.2	18
65	Spontaneous interleukin 2 release of bronchoalveolar lavage cells in sarcoidosis is a codeterminator of prognosis. Lung, 1996, 174, 243-53.	1.4	17
66	Vasoactive Intestinal Peptide in Checkpoint Inhibitorâ€"Induced Pneumonitis. New England Journal of Medicine, 2020, 382, 2573-2574.	13.9	17
67	CCL18 Production is Decreased in Alveolar Macrophages from Cigarette Smokers. Inflammation, 2009, 32, 163-168.	1.7	16
68	The chemokine CCL18 characterises<i>Pseudomonas</i>infections in cystic fibrosis lung disease. European Respiratory Journal, 2014, 44, 1608-1615.	3.1	16
69	Soluble CD90 as a potential marker of pulmonary involvement in systemic sclerosis. Arthritis Care and Research, 2013, 65, 281-287.	1.5	15
70	CCL18 â€" Potential Biomarker of Fibroinflammatory Activity in Chronic Periaortitis. Journal of Rheumatology, 2012, 39, 1407-1412.	1.0	14
71	A Cluster of Beryllium Sensitization Traced to the Presence of Beryllium in Concrete Dust. Chest, 2021, 159, 1084-1093.	0.4	14
72	Specific antigen(s) in sarcoidosis: a link to autoimmunity?. European Respiratory Journal, 2016, 47, 707-709.	3.1	13

#	Article	IF	Citations
73	Pharmacological modulation of the IFNÎ³-induced accessory function of alveolar macrophages and peripheral blood monocytes. Inflammation Research, 1999, 48, 662-668.	1.6	12
74	Inflammatory markers in exhaled breath condensate following lung resection for bronchial carcinoma. Respirology, 2008, 13, 1022-1027.	1.3	12
75	Bronchoalveolar Lavage Fluid Reflects a TH1-CD21low B-Cell Interaction in CVID-Related Interstitial Lung Disease. Frontiers in Immunology, 2020, 11, 616832.	2.2	12
76	Are bronchoalveolar lavages a good source for microbial profiling? Differences between throat and bronchoalveolar lavage microbiomes. Journal of Medical Microbiology, 2015, 64, 948-951.	0.7	12
77	Induction of accessory cell function of human alveolar macrophages by inhalation of human natural interleukin-2. Cancer Immunology, Immunotherapy, 1996, 42, 122-126.	2.0	11
78	Local administration of uridine suppresses the cardinal features of asthmatic airway inflammation. Clinical and Experimental Allergy, 2010, 40, 1552-1560.	1.4	11
79	mRNA and miRNA analyses in cytologically positive endobronchial ultrasoundâ€guided transbronchial needle aspiration: Implications for molecular staging in lung cancer patients. Cancer Cytopathology, 2014, 122, 292-298.	1.4	11
80	Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) â€" protocol for a multi-center, single-arm phase IIa trial. Contemporary Clinical Trials Communications, 2020, 19, 100575.	0.5	10
81	Formation of Granulomas in the Lungs of Severe Combined Immunodeficient Mice after Infection with Bacillus Calmette-Guerin. American Journal of Pathology, 2001, 158, 1890-1891.	1.9	9
82	Local Concentrations of CC-Chemokine-Ligand 18 Correlate with Tumor Size in Non-small Cell Lung Cancer and Are Elevated in Lymph Node-positive Disease. Anticancer Research, 2016, 36, 4667-4672.	0.5	8
83	Functional characterization of histamine receptor subtypes in a human bronchial epithelial cell line. International Journal of Molecular Medicine, 2006, 18, 925.	1.8	7
84	Turning back the Wheel: Inducing Mesenchymal to Epithelial Transition via Wilms Tumor 1 Knockdown in Human Mesothelioma Cell Lines to Influence Proliferation, Invasiveness, and Chemotaxis. Pathology and Oncology Research, 2017, 23, 723-730.	0.9	7
85	Accessory Function and Costimulatory Molecule Expression of Alveolar Macrophages in Patients with Pulmonary Tuberculosis. Immunobiology, 2000, 201, 450-460.	0.8	6
86	Generation and evaluation of a monoclonal antibody, designated MAdL, as a new specific marker for adenocarcinomas of the lung. British Journal of Cancer, 2011, 105, 673-681.	2.9	6
87	Sarcoidosis: Drugs under Investigation. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 532-537.	0.8	5
88	Roflumilast-N-oxide Induces Surfactant Protein Expression in Human Alveolar Epithelial Cells Type II. PLoS ONE, 2012, 7, e38369.	1.1	5
89	Is serum level of CC chemokine ligand 18 a biomarker for the prediction of radiation induced lung toxicity (RILT)?. PLoS ONE, 2017, 12, e0185350.	1.1	5
90	Surveillance Bronchoscopy for the Care of Lung Transplant Recipients: A Retrospective Single Center Analysis. Transplantation Proceedings, 2021, 53, 265-272.	0.3	4

#	Article	IF	Citations
91	Development of a new methodology to determine size differences of nanoparticles with nanoparticle tracking analysis. Applied Nanoscience (Switzerland), 2021, 11, 2129-2141.	1.6	4
92	Interaction Between CCL18 and GPR30 Differs from the Interaction Between Estradiol and GPR30. Anticancer Research, 2020, 40, 3097-3108.	0.5	3
93	Insights into immunometabolism: A dataset correlating the 18FDG PET/CT maximum standard uptake value of the primary tumor with the CCL18 serum level in non-small cell lung cancer. Data in Brief, 2021, 35, 106859.	0.5	3
94	Analysis of single nucleotide polymorphisms in chronic beryllium disease. Respiratory Research, 2021, 22, 107.	1.4	1
95	The Hidden Macrophage. Respiration, 2009, 77, 129-131.	1.2	0
96	Response. Chest, 2021, 159, 2509-2510.	0.4	0
97	Acute lung affection in an endurance-trained man under amiodarone medication. GMS German Medical Science, 2005, 3, Doc03.	2.7	0